Almirall reports core net sales growth in 2022 financial results

Almirall announced its financial results for 2022, which included a core net sales growth of 6.6% driven by its European sales, according to a company press release.

“We are pleased to see that Almirall achieved strong financial results in 2022, delivering our guidance thanks to the excellent evolution of our core dermatology business, which continues to perform well and is driven by our recently launched products and strengths in European business,” Carlos Gallardo, CEO and chairman of Almirall, said in the release.

The company achieved its 2022 guidance due to its business growth of 18.4% in Europe. Additionally, Almirall’s core net sales reached 863.2 million euros. Total earnings before interest, taxes, depreciation and amortization was 198.3 million euros, which was a 15.8% year-on-year decrease due mainly to the company’s higher investment in research, development and general expenses, according to the press release.

Growth drivers that contributed to Almirall’s performance include Ilumetri’s year-on-year sales increase (52.1%), as well as net sales of Klisyri (15 million euros) and Wynzora (7 million euros).

Pending a late 2023 approval, the company is currently anticipating a strong performance of lebrikizumab which was submitted in October 2022 for regulatory approval in the European Union.